GK
Therapeutic Areas
Libra Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lysofunction Platform / TRPML1 | Neurodegenerative Diseases (ALS, PD, etc.) | Preclinical |
| C9orf72 RAN Translation Inhibition | C9orf72-associated ALS/FTD | Discovery |
| C9orf72 Transcriptional Modification | C9orf72-associated ALS/FTD | Discovery |
| Undisclosed Target | Not Disclosed | Discovery |
Leadership Team at Libra Therapeutics
SS
Shawn Scranton, PharmD
Chief Executive Officer & President
MG
Martin Gill, PhD
Chief Scientific Officer